PMID- 18700946
OWN - NLM
STAT- MEDLINE
DCOM- 20081201
LR  - 20211020
IS  - 1526-4610 (Electronic)
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 48 Suppl 2
IP  - Suppl 2
DP  - 2008 Jul
TI  - Estrogen-growth factor interactions and their contributions to neurological 
      disorders.
PG  - S77-89
LID - 10.1111/j.1526-4610.2008.01200.x [doi]
AB  - Estrogen has diverse and powerful effects in the brain, including actions on 
      neurons, glia, and the vasculature. It is not surprising, therefore, that there 
      are many changes in the female brain as serum estradiol levels rise and fall 
      during the normal ovarian cycle. At times of life when estradiol levels change 
      dramatically, such as puberty, postpartum, or menopause, there also are dramatic 
      changes in the central nervous system. Changes that occur because of fluctuations 
      in serum estrogen levels are potentially relevant to neurological disorders 
      because symptoms often vary with the time of the ovarian cycle. Moreover, 
      neurological disorders (eg, seizures and migraine) often increase in frequency in 
      women when estradiol levels change. In this review, the contribution of 2 growth 
      factors targeted by estrogen, the neurotrophin brain-derived neurotrophic factor 
      (BDNF) and vascular endothelial growth factor (VEGF), will be discussed. 
      Estrogen-sensitive response elements are present on the genes for both BDNF and 
      VEGF, and they are potent modulators of neuronal, glial, and vascular function, 
      making them logical candidates to mediate the multitude of effects of estrogen. 
      In addition, BDNF induces neuropeptide Y, which has diverse actions that are 
      relevant to estrogen action and to the same neurological disorders.
FAU - Scharfman, Helen E
AU  - Scharfman HE
AD  - Nathan Kline Institute for Psychiatric Research & New York University School of 
      Medicine, Orangeburg, NY 10962, USA.
FAU - MacLusky, Neil J
AU  - MacLusky NJ
LA  - eng
GR  - R56 NS037562/NS/NINDS NIH HHS/United States
GR  - R56 NS037562-11A1/NS/NINDS NIH HHS/United States
GR  - NINDS 37562/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Estrogens)
RN  - 0 (Neuropeptide Y)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*physiology
MH  - Estradiol/physiology
MH  - Estrogens/*physiology
MH  - Female
MH  - Humans
MH  - Migraine Disorders/physiopathology
MH  - Nervous System Diseases/*physiopathology
MH  - Neuropeptide Y/physiology
MH  - Vascular Endothelial Growth Factor A/*physiology
PMC - PMC2729400
MID - NIHMS126020
EDAT- 2008/10/29 09:00
MHDA- 2008/12/17 09:00
PMCR- 2009/08/20
CRDT- 2008/10/29 09:00
PHST- 2008/10/29 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/10/29 09:00 [entrez]
PHST- 2009/08/20 00:00 [pmc-release]
AID - HED1200 [pii]
AID - 10.1111/j.1526-4610.2008.01200.x [doi]
PST - ppublish
SO  - Headache. 2008 Jul;48 Suppl 2(Suppl 2):S77-89. doi: 
      10.1111/j.1526-4610.2008.01200.x.